Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.